97. 潰瘍性大腸炎 Ulcerative colitis Clinical trials / Disease details


臨床試験数 : 2,630 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05118919
(ClinicalTrials.gov)
February 9, 202226/10/2021A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative ColitisA Randomised Placebo-controlled Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Mild to Moderate Ulcerative ColitisUlcerative ColitisBiological: BGP-014;Biological: PlaceboBioGaia Pharma ABNULLRecruiting18 YearsN/AAll50Phase 1/Phase 2Sweden
2EUCTR2019-004578-25-SE
(EUCTR)
09/07/202127/12/2019A clinical study in patients with mild to moderate ulcerative colitis to test the tolerability of Lactobacillus reuteri BGP-014A randomised placebo-controlled safety study of Lactobacillus reuteri BGP-014 in patients with active mild to moderate ulcerative colitis Mild to moderate ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: BGP-014 Capsules
Product Code: BGP-014
INN or Proposed INN: Lactobacillus reuteri
Other descriptive name: LACTOBACILLUS REUTERI
BioGaia Pharma ABNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Phase 1;Phase 2Sweden